EUCTR2020-004561-39-PL进行中（未招募）1 期
A phase 2 trial to evaluate the efficacy and safety of orally administered LEO 152020 tablets compared with placebo tablets for up to 16 weeks of treatment in adults with moderate to severe atopic dermatitis
EO Pharma A/S0 个研究点目标入组 224 人开始时间: 2021年5月27日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 224
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •The subjects must fulfil all of the following criteria to be eligible for the
- •Adult, age 18 years or older at screening.
- •Diagnosis of chronic atopic dermatitis (AD).
- •History of AD =1 year prior to baseline.
- •Recent (within 6 months prior to baseline) documented history of inadequate response to topical AD treatments or subject for whom topical AD treatments are medically inadvisable.
- •7.1= EASI =50 at baseline
- •vIGA AD score =3 at baseline.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 214
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •Subjects are not eligible for the trial if they violate any of the following criteria:
- •Previous treatment with an oral H4R antagonist (including LEO 152020) within 6 months prior to baseline.
- •Previous treatment with 3 or more systemic AD treatments prior to screening.
- •Women who are pregnant or lactating.
研究者
相似试验
进行中（未招募）
1 期
A phase 2 trial to evaluate the efficacy and safety of orally-administered LEO 152020 tablets compared with placebo tablets for up to 16 weeks of treatment in adults with moderate to severe atopic dermatitis (eczema)Atopic Dermatitis (AD)MedDRA version: 21.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858EUCTR2020-004561-39-DEEO Pharma A/S224
进行中（未招募）
1 期
Efficacy and safety of different dose regimens of LEO 152020 tablets for the treatment of adults with moderate to severe atopic dermatitis up to 16 weeksAtopic Dermatitis (AD)MedDRA version: 21.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858EUCTR2020-004561-39-CZEO Pharma A/S224
进行中（未招募）
1 期
A phase 2 trial to evaluate the efficacy and safety of orally-administered LEO 152020 tablets compared with placebo tablets for up to 16 weeks of treatment in adults with moderate to severe atopic dermatitis (eczema)Atopic Dermatitis (AD)MedDRA version: 21.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858EUCTR2020-004561-39-ESEO Pharma A/S224
已完成
2 期
Efficacy and Safety of LEO 152020 Tablets for the Treatment of Adults With Moderate to Severe Atopic DermatitisAtopic DermatitisJPRN-jRCT2031210485Kikuchi Aki224
招募中
2 期
Safety and Efficacy study of repeated MPA therapy for recurrent early stage endometrial cancer patients (JGOG2051)JPRN-jRCTs031200256Yamagami Wataru115